175 related articles for article (PubMed ID: 33455693)
1. [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology].
Navarro S; Cuatrecasas M; Hernández-Losa J; Landolfi S; Musulén E; Ramón Y Cajal S; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; García-Alfonso P
Rev Esp Patol; 2021; 54(1):41-54. PubMed ID: 33455693
[TBL] [Abstract][Full Text] [Related]
2. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
García-Alfonso P; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; Ramón Y Cajal S; Hernández-Losa J; Landolfi S; Musulén E; Cuatrecasas M; Navarro S
Clin Transl Oncol; 2020 Nov; 22(11):1976-1991. PubMed ID: 32418154
[TBL] [Abstract][Full Text] [Related]
3. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P; García-Foncillas J; Salazar R; Pérez-Segura P; García-Carbonero R; Musulén-Palet E; Cuatrecasas M; Landolfi S; Ramón Y Cajal S; Navarro S; ;
Clin Transl Oncol; 2015 Apr; 17(4):264-73. PubMed ID: 25373533
[TBL] [Abstract][Full Text] [Related]
4. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
7. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
8. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
9. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
García-Alfonso P; Salazar R; García-Foncillas J; Musulén E; García-Carbonero R; Payá A; Pérez-Segura P; Ramón y Cajal S; Navarro S; ;
Clin Transl Oncol; 2012 Oct; 14(10):726-39. PubMed ID: 22855150
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
13. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
[TBL] [Abstract][Full Text] [Related]
14. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki K; Taniguchi H; Yoshino T; Akagi K; Ishida H; Ebi H; Nakatani K; Muro K; Yatabe Y; Yamaguchi K; Tsuchihara K
Cancer Sci; 2018 Jun; 109(6):2074-2079. PubMed ID: 29873882
[TBL] [Abstract][Full Text] [Related]
15. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
17. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
19. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
20. KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.
Barresi V; Bonetti LR; Bettelli S
Pathology; 2015 Oct; 47(6):551-6. PubMed ID: 26352110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
